8-K: Charlottes Web Q1 2026: BAT Deal Nears, Healthcare Pathway Opens

Charlottes Web announced Q1 2026 results, highlighting progress on a transformative transaction with BAT, the activation of a CMS healthcare access pathway, and continued improvement in Adjusted EBITDA.

Summary

• Charlottes Web reported Q1 2026 revenue of $11.2 million, a decrease from $12.3 million in Q1 2025, primarily due to exiting lower-margin retail relationships.
• The company is progressing with a significant transaction with BAT, which includes converting a $54 million convertible debenture and a $10 million private placement, expected to strengthen the balance sheet and reduce annual interest costs by approximately $3 million.
• The Centers for Medicare & Medicaid Services (CMS) activated an optional Substance Access Beneficiary Engagement Incentive (BEI) on April 1, 2026, allowing eligible beneficiaries to receive up to $500 annually in hemp-derived CBD products, with Charlottes Web preparing for this opportunity.
• DeFloria, a collaboration for an investigational botanical drug candidate (AJA001) for irritability associated with autism spectrum disorder (ASD), is advancing its Phase 2 clinical program, with trial initiation expected in mid-2026.
• In-house gummy production is substantially complete, with expectations of improved gross margins as production scales.
• Adjusted EBITDA improved by $1.1 million year-over-year to a loss of $1.7 million in Q1 2026, from a loss of $2.8 million in Q1 2025.
• The company qualified for trading on the OTCQX Best Market, an upgrade from the OTCQB Venture Market, enhancing visibility for U.S. investors.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic filing, with significant strategic progress and potential balance sheet improvements offset by near-term revenue declines and ongoing operational challenges.

Positives

• The proposed transaction with BAT is expected to eliminate Charlottes Web's largest balance sheet liability, reduce annual interest costs by approximately $3 million, strengthen shareholders' equity, and provide $10 million in new capital.
• Activation of the CMS BEI program on April 1, 2026, presents a significant new healthcare channel opportunity for eligible hemp-derived CBD products.
• Adjusted EBITDA improved by $1.1 million year-over-year, indicating progress in operational efficiency and cost management.
• SG&A expenses decreased by 17.7% year-over-year, reflecting successful cost optimization efforts.
• In-house gummy manufacturing is nearing completion, which is expected to improve gross margins.
• Qualification for the OTCQX Best Market enhances the company's profile and accessibility to U.S. investors.

Negatives

• Consolidated net revenue decreased by 9.0% to $11.2 million in Q1 2026 compared to $12.3 million in Q1 2025, primarily due to exiting lower-margin retail relationships.
• Gross profit margin decreased to 46.6% in Q1 2026 from 50.8% in Q1 2025, attributed to higher production costs, legacy inventory, and increased online promotional investment.
• The company reported a net loss of $13.1 million in Q1 2026, compared to a net loss of $6.2 million in Q1 2025, partly due to a non-cash fair value adjustment on the BAT convertible debenture.
• Cash and cash equivalents decreased to $5.2 million as of March 31, 2026, from $19.4 million as of March 31, 2025.

Risks

• The BEI program remains subject to ongoing legal and administrative scrutiny, and the Company is monitoring any risks, litigation, and implications.
• The DeFloria Phase 2 clinical program is subject to clinical, regulatory, financing, and commercialization risks.
• The proposed transaction with BAT is subject to TSX approval and shareholder approval at the Annual General and Special Meeting on May 28, 2026.
• Forward-looking statements are subject to various risks and uncertainties, including regulatory changes, market conditions, and the successful completion of the BAT transaction.

Future Outlook

Management expects gross margin to trend toward approximately 50% as insourced production efficiencies scale and transitional costs normalize. Quarterly SG&A is expected to remain in a normalized range of approximately $10 million. Management believes existing cash and cash equivalents will provide sufficient liquidity to fund operations and planned capital expenditures for the next 12 months.

Management Comments

• "Charlottes Web exited the first quarter with the right elements in place to position us for future growth. With a significantly enhanced capital structure and balance sheet on the horizon, along with our first-class product-quality systems, and rapidly emerging healthcare-channel infrastructure, we are well prepared to pursue the fast evolving federally authorized CBD opportunities."
• "Following the April 1 activation of the CMS Substance Access Beneficiary Engagement Incentive, we are moving from preparation to deployment while continuing support for federal regulatory clarity and advancing DeFloria through the FDA Botanical Drug Pathway."
• "Our Q1 2026 results reflect continued progress on the operational fundamentals of the business."
• "Lower first-quarter revenue reflects our decision to exit select lower-margin retail relationships last September and reduce the cost structure required to support those accounts. While this reduces near-term revenue, it improves the quality of our product and channel mix, and is expected to support stronger gross margin, operating margin, and cash flow over time."
• "We are focused on profitable revenue, disciplined resource allocation, and building a more scalable business. Our core online consumer channel demonstrated healthy engagement, while operational discipline further improved cash flow."

Industry Context

StockSavvy.ai notes that Charlottes Web's strategic focus on the emerging CMS healthcare access pathway and its advancement of a botanical drug candidate align with broader industry trends towards greater regulatory clarity and pharmaceutical development within the wellness sector. The proposed transaction with BAT, a major global player, signals a potential consolidation and validation of the hemp-derived wellness market.

Related Party Transactions

• The transaction with BAT involves the conversion of BAT's outstanding convertible debenture and a concurrent $10 million private placement. Post-transaction, BAT would hold approximately 40% of the company's common shares.

Stakeholder Impact

• Shareholders: Potential for a strengthened balance sheet, reduced interest costs, and increased equity upon completion of the BAT transaction. Shareholder approval is required for the transaction.
• Creditors: The conversion of the convertible debenture will eliminate the company's largest outstanding liability.
• Employees: Continued focus on operational discipline and a lean cost base to support growth.
• Customers: Continued access to quality CBD products, with potential for expanded access through the CMS BEI program.

Next Steps

• Obtain TSX approval for the transaction with BAT.
• Obtain shareholder approval for the transaction with BAT at the Annual General and Special Meeting on May 28, 2026.
• Complete the transaction with BAT, which includes converting the convertible debenture and completing the $10 million private placement.
• Advance the Phase 2 clinical program for DeFloria (AJA001) with trial initiation expected in mid-2026.
• Continue to prepare for and deploy participation in the CMS BEI program, with visibility into adoption expected in the second half of the year.

Key Dates

Recommendation

The company is at a critical juncture with the proposed BAT transaction poised to significantly improve its financial standing and strategic positioning. However, near-term revenue declines and the inherent risks associated with clinical trials and regulatory pathways warrant a cautious 'hold' stance until the transaction closes and the impact of new healthcare initiatives becomes clearer.

Keywords

Charlottes Web, CBD, Hemp Extract, BAT, CMS, BEI Program, Botanical Drug, Q1 2026 Results